Table 1 Baseline features of the study cohort (n = 226)
Males, n (%) | 111 (49.1%) |
Age at enrolment, median (IQR) years | 46.9 (35.6–55.2) |
Disease duration, median (IQR) years | 11.7 (5.9–20.8) |
Comorbidities, n (%) | 99 (43.8%) |
Active disease manifestations | |
Mucocutaneous lesions, n (%) | 83 (36.7%) |
Ocular involvement, n (%) | 12 (5.3%) |
Arthritis, n (%) | 17 (7.5%) |
Major organ involvement, n (%) | 20 (8.8%) |
Disease activity indices | |
PGA, median (IQR) score | 1.0 (0.0–3.0) |
PtGA, median (IQR) score | 2.0 (0.3–5.0) |
BDCAF, median (IQR) score | 3.0 (0.0–5.0) |
Irreversible organ damage | |
BODI, median (IQR) score | 1.0 (0.0–2.0) |
HR-QoL (by SF-26) | |
PCS, median (IQR) score | 46.6 (38.8–54.2) |
MCS, median (IQR) score | 44.9 (35.9–54.4) |
Current and past therapy | |
Colchicine, n (%) | 107 (47.3%) |
Glucocorticoids, n (%) | 104 (45.6%) |
Immunosuppressants, n (%) | 95 (42.0%) |
Biologics, n (%) | 49 (21.7%) |